866-997-4948(US-Canada Toll Free)

Rubella (German Measles) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 45 Pages

Rubella (German Measles) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rubella (German Measles) Pipeline Review, H2 2016, provides an overview of the Rubella (German Measles) (Infectious Disease) pipeline landscape.

Rubella also known as the German measles is an acute, contagious viral infection. The rubella virus is transmitted by airborne droplets when infected people sneeze or cough. Symptoms include fever, headache, stuffy or runny nose, inflamed, red eyes, aching joints and enlarged, tender lymph nodes at the base of the skull, the back of the neck and behind the ears.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rubella (German Measles) Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Rubella (German Measles) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rubella (German Measles) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rubella (German Measles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 2, 1, 2, 1 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.Rubella (German Measles).

Rubella (German Measles) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Rubella (German Measles) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Rubella (German Measles) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rubella (German Measles) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rubella (German Measles) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Rubella (German Measles) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Rubella (German Measles) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Rubella (German Measles) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Rubella (German Measles) Overview 6
Therapeutics Development 7
Pipeline Products for Rubella (German Measles) - Overview 7
Pipeline Products for Rubella (German Measles) - Comparative Analysis 8
Rubella (German Measles) - Therapeutics under Development by Companies 9
Rubella (German Measles) - Therapeutics under Investigation by Universities/Institutes 10
Rubella (German Measles) - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Rubella (German Measles) - Products under Development by Companies 15
Rubella (German Measles) - Products under Investigation by Universities/Institutes 16
Rubella (German Measles) - Companies Involved in Therapeutics Development 17
Beijing Minhai Biotechnology Co., Ltd 17
Beijing Tiantan Biological Products Co., Ltd. 18
Biological E. Limited 19
Daiichi Sankyo Company, Limited 20
GlaxoSmithKline Plc 21
Indian Immunologicals Limited 22
Prometheon Pharma, LLC 23
Sinovac Biotech Ltd. 24
Zydus Cadila Healthcare Limited 25
Rubella (German Measles) - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
(measles + mumps + rubella + varicella) vaccine - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
(measles + mumps + rubella + varicella) vaccine - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
(measles + mumps + rubella) vaccine - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
(measles + mumps + rubella) vaccine - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
(measles + mumps + rubella) vaccine - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
(measles + rubella + varicella) vaccine - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
(measles + rubella) vaccine - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
(measles + rubella) vaccine - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
(measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
rubella vaccine - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
VN-0102 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Rubella (German Measles) - Dormant Projects 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 44
Disclaimer 45

List of Tables
Number of Products under Development for Rubella (German Measles), H2 2016 7
Number of Products under Development for Rubella (German Measles) - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Comparative Analysis by Unknown Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
l 16
Rubella (German Measles) - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016 17
Rubella (German Measles) - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2016 18
Rubella (German Measles) - Pipeline by Biological E. Limited, H2 2016 19
Rubella (German Measles) - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 20
Rubella (German Measles) - Pipeline by GlaxoSmithKline Plc, H2 2016 21
Rubella (German Measles) - Pipeline by Indian Immunologicals Limited, H2 2016 22
Rubella (German Measles) - Pipeline by Prometheon Pharma, LLC, H2 2016 23
Rubella (German Measles) - Pipeline by Sinovac Biotech Ltd., H2 2016 24
Rubella (German Measles) - Pipeline by Zydus Cadila Healthcare Limited, H2 2016 25
Assessment by Monotherapy Products, H2 2016 26
Assessment by Combination Products, H2 2016 27
Number of Products by Stage and Route of Administration, H2 2016 29
Number of Products by Stage and Molecule Type, H2 2016 31
Rubella (German Measles) - Dormant Projects, H2 2016 43

List of Figures
Number of Products under Development for Rubella (German Measles), H2 2016 7
Number of Products under Development for Rubella (German Measles) - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Assessment by Monotherapy Products, H2 2016 26
Assessment by Combination Products, H2 2016 27
Number of Products by Routes of Administration, H2 2016 28
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 28
Number of Products by Molecule Types, H2 2016 30
Number of Products by Stage and Molecule Types, H2 2016 30

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *